Annual CFF
$166.94 M
-$338.28 M-66.96%
31 December 2022
Summary:
Mirati Therapeutics annual cash flow from financing activities is currently $166.94 million, with the most recent change of -$338.28 million (-66.96%) on 31 December 2022. During the last 3 years, it has fallen by -$338.28 million (-66.96%).MRTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$334.70 M
+$330.86 M+8609.34%
30 September 2023
Summary:
Mirati Therapeutics quarterly cash flow from financing activities is currently $334.70 million, with the most recent change of +$330.86 million (+8609.34%) on 30 September 2023.MRTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$346.19 M
+$177.59 M+105.34%
30 September 2023
Summary:
Mirati Therapeutics TTM cash flow from financing activities is currently $346.19 million, with the most recent change of +$177.59 million (+105.34%) on 30 September 2023.MRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -67.0% | -30.2% | -31.5% |
| 5 y5 years | -50.6% | +9537.2% | +2.4% |
MRTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -86.7% | -62.4% | -72.3% |
Mirati Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | $334.70 M(+8609.3%) | $346.19 M(+105.3%) |
| June 2023 | - | $3.84 M(+122.5%) | $168.59 M(+1.5%) |
| Mar 2023 | - | $1.73 M(-70.8%) | $166.14 M(-0.5%) |
| Dec 2022 | $166.94 M(-67.0%) | $5.92 M(-96.2%) | $166.94 M(-73.9%) |
| Sept 2022 | - | $157.10 M(>+9900.0%) | $640.31 M(+30.3%) |
| June 2022 | - | $1.39 M(-44.9%) | $491.43 M(-1.3%) |
| Mar 2022 | - | $2.53 M(-99.5%) | $497.86 M(-1.5%) |
| Dec 2021 | $505.22 M(-59.6%) | $479.28 M(+5722.2%) | $505.22 M(-44.8%) |
| Sept 2021 | - | $8.23 M(+5.2%) | $915.83 M(-0.4%) |
| June 2021 | - | $7.82 M(-20.9%) | $919.95 M(-0.2%) |
| Mar 2021 | - | $9.88 M(-98.9%) | $921.40 M(-26.3%) |
| Dec 2020 | $1.25 B(+270.0%) | $889.89 M(+7105.0%) | $1.25 B(+243.3%) |
| Sept 2020 | - | $12.35 M(+33.2%) | $364.30 M(+3.2%) |
| June 2020 | - | $9.27 M(-97.3%) | $353.02 M(-37.6%) |
| Mar 2020 | - | $339.20 M(+9666.8%) | $565.63 M(+67.3%) |
| Dec 2019 | $338.03 M(+140.0%) | $3.47 M(+224.0%) | $338.03 M(+0.9%) |
| Sept 2019 | - | $1.07 M(-99.5%) | $335.02 M(-0.3%) |
| June 2019 | - | $221.88 M(+98.8%) | $336.10 M(+36.3%) |
| Mar 2019 | - | $111.60 M(>+9900.0%) | $246.56 M(+75.1%) |
| Dec 2018 | $140.85 M(-11.2%) | $462.00 K(-78.6%) | $140.85 M(-38.8%) |
| Sept 2018 | - | $2.16 M(-98.4%) | $230.03 M(+0.0%) |
| June 2018 | - | $132.34 M(+2146.9%) | $230.02 M(+135.3%) |
| Mar 2018 | - | $5.89 M(-93.4%) | $97.75 M(-38.4%) |
| Dec 2017 | $158.68 M(+5883.3%) | $89.64 M(+4071.3%) | $158.68 M(+129.6%) |
| Sept 2017 | - | $2.15 M(+2926.8%) | $69.10 M(+3.2%) |
| June 2017 | - | $71.00 K(-99.9%) | $66.95 M(-0.3%) |
| Mar 2017 | - | $66.82 M(>+9900.0%) | $67.14 M(+2431.7%) |
| Dec 2016 | $2.65 M(-98.2%) | $60.00 K(>+9900.0%) | $2.65 M(-10.0%) |
| Sept 2016 | - | $0.00(-100.0%) | $2.95 M(-97.0%) |
| June 2016 | - | $266.00 K(-88.6%) | $98.02 M(-0.1%) |
| Mar 2016 | - | $2.33 M(+555.2%) | $98.09 M(-32.1%) |
| Dec 2015 | $144.37 M(>+9900.0%) | $355.00 K(-99.6%) | $144.37 M(+0.0%) |
| Sept 2015 | - | $95.07 M(>+9900.0%) | $144.36 M(+192.3%) |
| June 2015 | - | $335.00 K(-99.3%) | $49.39 M(+0.3%) |
| Mar 2015 | - | $48.61 M(>+9900.0%) | $49.23 M(+5450.3%) |
| Dec 2014 | $887.00 K | $351.00 K(+251.0%) | $887.00 K(-98.4%) |
| Sept 2014 | - | $100.00 K(-42.5%) | $55.27 M(+0.1%) |
| June 2014 | - | $174.00 K(-33.6%) | $55.19 M(+0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $262.00 K(-99.5%) | $55.02 M(+0.5%) |
| Dec 2013 | $54.76 M(+120.7%) | $54.73 M(>+9900.0%) | $54.76 M(+120.3%) |
| Sept 2013 | - | $22.00 K(>+9900.0%) | $24.85 M(+0.1%) |
| June 2013 | - | $0.00(0.0%) | $24.83 M(+0.1%) |
| Mar 2013 | - | $0.00(-100.0%) | $24.82 M(+0.0%) |
| Dec 2012 | $24.81 M(-22.1%) | $24.83 M(>+9900.0%) | $24.81 M(+5018.2%) |
| Sept 2012 | - | $0.00(-100.0%) | $484.80 K(-127.9%) |
| June 2012 | - | -$13.00 K(+333.3%) | -$1.74 M(-105.6%) |
| Mar 2012 | - | -$3000.00(-100.6%) | $31.05 M(-2.5%) |
| Dec 2011 | $31.84 M(+414.4%) | $500.80 K(-122.6%) | $31.84 M(+1.2%) |
| Sept 2011 | - | -$2.22 M(-106.8%) | $31.45 M(-6.9%) |
| June 2011 | - | $32.77 M(+4063.3%) | $33.78 M(+384.3%) |
| Mar 2011 | - | $787.10 K(+578.0%) | $6.98 M(+12.7%) |
| Dec 2010 | $6.19 M(+380.0%) | $116.10 K(+5.1%) | $6.19 M(-15.9%) |
| Sept 2010 | - | $110.50 K(-98.1%) | $7.36 M(+1.5%) |
| June 2010 | - | $5.96 M(>+9900.0%) | $7.25 M(+462.5%) |
| Mar 2010 | - | $0.00(-100.0%) | $1.29 M(0.0%) |
| Dec 2009 | $1.29 M(>+9900.0%) | $1.29 M(>+9900.0%) | $1.29 M(>+9900.0%) |
| Sept 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| June 2009 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2008 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2008 | - | $0.00(0.0%) | $46.80 K(-96.5%) |
| June 2008 | - | $0.00(0.0%) | $1.32 M(-51.1%) |
| Mar 2008 | - | $0.00(-100.0%) | $2.71 M(-85.7%) |
| Dec 2007 | $18.97 M(-17.5%) | $46.80 K(-96.3%) | $18.97 M(+6.0%) |
| Sept 2007 | - | $1.28 M(-7.8%) | $17.90 M(+8.0%) |
| June 2007 | - | $1.38 M(-91.5%) | $16.58 M(-53.1%) |
| Mar 2007 | - | $16.27 M(-1687.3%) | $35.35 M(+53.7%) |
| Dec 2006 | $23.01 M(<-9900.0%) | -$1.02 M(+1974.5%) | $23.01 M(-4.2%) |
| Sept 2006 | - | -$49.40 K(-100.2%) | $24.03 M(-0.2%) |
| June 2006 | - | $20.16 M(+414.1%) | $24.07 M(+514.7%) |
| Mar 2006 | - | $3.92 M(<-9900.0%) | $3.92 M(<-9900.0%) |
| Dec 2005 | -$3600.00(-100.0%) | -$4300.00(+2.4%) | -$3600.00(-614.3%) |
| Sept 2005 | - | -$4200.00(-213.5%) | $700.00(-85.7%) |
| June 2005 | - | $3700.00(+208.3%) | $4900.00(+308.3%) |
| Mar 2005 | - | $1200.00 | $1200.00 |
| Dec 2004 | $16.84 M(+1124.3%) | - | - |
| Dec 2003 | $1.38 M | - | - |
FAQ
- What is Mirati Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Mirati Therapeutics?
- What is Mirati Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Mirati Therapeutics?
What is Mirati Therapeutics annual cash flow from financing activities?
The current annual CFF of MRTX is $166.94 M
What is the all time high annual CFF for Mirati Therapeutics?
Mirati Therapeutics all-time high annual cash flow from financing activities is $1.25 B
What is Mirati Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of MRTX is $334.70 M
What is the all time high quarterly CFF for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly cash flow from financing activities is $889.89 M
What is Mirati Therapeutics TTM cash flow from financing activities?
The current TTM CFF of MRTX is $346.19 M
What is the all time high TTM CFF for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM cash flow from financing activities is $1.25 B